XT
SGMO

XTX Topco’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

XTX Topco’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.75K Sell
39,474
-144,057
-78% -$57.3K ﹤0.01% 3691
2025
Q4 		$77.1K Buy
+183,531
New +$97.3K ﹤0.01% 2712
2025
Q3 		– Sell
-76,413
Closed -$41.4K – 3193
2025
Q2 		$41.4K Buy
+76,413
New +$45.4K ﹤0.01% 2054
2025
Q1 		– Sell
-21,817
Closed -$22.3K – 3022
2024
Q4 		$22.3K Sell
21,817
-81,899
-79% -$150K ﹤0.01% 2023
2024
Q3 		$89.8K Buy
103,716
+64,981
+168% +$47.6K 0.01% 1622
2024
Q2 		$13.9K Buy
38,735
+12,711
+49% +$6.87K ﹤0.01% 1658
2024
Q1 		$17.4K Buy
+26,024
New +$18.9K ﹤0.01% 1626
2023
Q4 		– Sell
-46,486
Closed -$27.9K – 2079
2023
Q3 		$27.9K Sell
46,486
-211,172
-82% -$226K ﹤0.01% 1344
2023
Q2 		$335K Buy
257,658
+51,324
+25% +$70.1K 0.06% 637
2023
Q1 		$363K Buy
206,334
+160,600
+351% +$458K 0.08% 504
2022
Q4 		$144K Buy
45,734
+8,617
+23% +$33.4K 0.03% 933
2022
Q3 		$182K Buy
+37,117
New +$191K 0.05% 815

Other funds holding SGMO

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

XTX Topco's SGMO Position: Q1 2026 in Review

XTX Topco reduced its SANGAMO THERAPEUTICS INC (SGMO) stake by 78% in Q1 2026, selling an estimated $57.3K and leaving 39,474 shares worth $9.75K. The position accounts for ﹤0.01% of the portfolio, ranked #3691.

XTX Topco first reported a position in SGMO in Q3 2022 and has held it in 12 quarters since. The position peaked at $363K in Q1 2023. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

  • XTX Topco held 39,474 shares of SANGAMO THERAPEUTICS INC worth $9.75K as of Q1 2026.
  • XTX Topco sold 144,057 SANGAMO THERAPEUTICS INC shares in Q1 2026, an estimated $57.3K.
  • SANGAMO THERAPEUTICS INC made up ﹤0.01% of XTX Topco's portfolio in Q1 2026, its #3691 holding.
  • XTX Topco first reported a position in SANGAMO THERAPEUTICS INC in Q3 2022 and has held it in 12 quarters since.
  • XTX Topco's SANGAMO THERAPEUTICS INC position peaked at $363K in Q1 2023.
  • 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.